Physician profile
Edward Kitces
NPI 1336142306
$6,732.17
in general payments reported to CMS, 2019-2025
27 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $478 · 2021: $955 · 2022: $649 · 2023: $1,095 · 2024: $1,379 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282 · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.31 |
| Education | $352.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,567.73 | 2019-2025 | |
| Janssen Biotech, INC. | $1,329.69 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $515.29 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $463.55 | 2019-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $370.56 | 2023-2025 | Zoryve |
| Hill Dermaceuticals, INC. | $333.30 | 2025 | Tolak |
| Pfizer INC. | $307.39 | 2019-2025 | |
| Lilly USA, LLC | $243.99 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Regeneron Healthcare Solutions, INC. | $241.04 | 2019-2025 | Dupixent |
| Genzyme Corporation | $238.78 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $211.73 | 2019-2021 | |
| Incyte Corporation | $146.20 | 2023-2024 | Opzelura |
| Galderma Laboratories, L.P. | $131.84 | 2019-2025 | Aklief |
| Sun Pharmaceutical Industries INC. | $119.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $105.32 | 2024-2025 | Sotyktu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $83.41 | 2022-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.15 | 2022-2024 | Spevigo |
| Mallinckrodt Hospital Products INC. | $48.57 | 2021 | |
| Organon LLC | $44.59 | 2025 | Vtama |
| Prugen, INC. Pharmaceuticals | $37.75 | 2019 | |
| Mayne Pharma Commercial LLC | $35.35 | 2019 | |
| Ani Pharmaceuticals, INC. | $26.20 | 2025 | Purified Cortrophin Gel |
| Dermavant Sciences, INC. | $19.10 | 2024 | Vtama |
| Almirall LLC | $18.38 | 2021 | |
| Medtronic Vascular, INC. | $15.36 | 2020 | |
| Mission Pharmacal Company | $15.00 | 2021 | |
| Sebela Pharmaceuticals INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kitces listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.